Microbiota Modification for the Treatment of Motor Complication of Parkinson´s Disease
Microbiota Modification for the Treatment of Motor Complication of Parkinson´s Disease
In recent years, abnormalities in gut microbiota have been identified in patients with
 Parkinson´s disease having a possible role in motor manifestations. Among 80 patients with
 PD, we selected 14 with LID and motor fluctuations with limited response to pharmacological
 therapy to receive treatment with sodium phosphate enema, oral rifaximin and polyethylene
 glycol to improve motor complications.
We studied consecutive patients diagnosed with PD according to the Queen Square Brain Bank
 Criteria [Hughes et al 1992] in a tertiary care center for movement disorders, from June 2018
 to March 2020.
Inclusion Criteria:

 - patients aged 18-years old or older with moderate to severe dyskinesia and/or motor
 fluctuations with incomplete or poor response to adjustments in time and dose of levodopa
 and other anti-parkinsonian agents such as entacapone, rasagiline, dopamine receptor
 agonists and amantadine in 1-2 months prior to enrollment; defined by a Movement Disorders
 Society Unified Parkinson´s Disease Rating Scale (MDS-UPDRS) part IV score equal or higher
 than 8 following pharmacological adjustments.

 Exclusion Criteria:

 -  patients with chronic renal failure, decompensated heart failure, colonic
 abnormalities precluding the use of evacuating enema, known allergies to prescribed
 medications to reduce microbiota load and patients who declined to participate in the
 study.